Clinical Trial Update: A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). [Phase 3]

View source ↗

Summary

A phase 3 trial (GLOW) evaluating zolbetuximab plus CAPOX versus placebo plus CAPOX in CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma has posted re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Oxaliplatin (Eloxatin) (oxaliplatin)
• Zolbetuximab (IMAB362) (zolbetuximab)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-01-27